Our study provides compelling real-world evidence that SGLT2 inhibitor therapy in MASLD patients is associated with substantial reductions in mortality, advanced liver disease, and cardiovascular events over 10 years of follow-up. The gene discussed is SLC5A2; the disease is liver disorder.